Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer
Cambridge, UK: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, announces the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenur
PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec
ArgusEye closes €2.8 million funding to accelerate bioprocessing
Led by Voima Ventures and co-led by existing investor Eir Ventures Funding will support continued development of Auga sensor system platform to accelerate the bioprocessing workflow from early upstream to late formulationStockholm, Sweden
ERS Genomics appoints John E Milad as Chief Executive Officer
Dublin, Ireland: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announces the appointment of John E Milad as CEO, with immediate effect.
Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment
Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples
Bio-Rad launches three StarBright Red Dyes and expands range of antibody markers conjugated to StarBright Violet Dyes to enhance immunology research
Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.
PlaqueTec closes $8 million equity financing
The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform the treatment of CADCambridge, UK, 30
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
Stable lentiviral (LV) cell line development service achieves unconcentrated titers >1E9 TU/mL for therapeutic transgenes.Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs
Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.
Zyme Communications expands UK head office with new facilities at Cambridge Innovation Park
Investment in new headquarters forms part of ongoing company growth plans and supports Zyme’s continued success, following client base and team expansion.
Sphere Fluidics appoints Edward Rayner as Non-Executive Director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth.
Bio-Rad announces collaboration agreement with Oncocyte to commercialize transplant monitoring with Droplet Digital PCR
Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants
Metrion Biosciences enhances High Throughput Screening services with access to Enamine compound libraries
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Preci and Biopredic International partner for higher performance of suspended pooled hepatocytes with extended longevity and large-scale availability
License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies
Bio-Rad and Allegheny Health Network Cancer Institute collaborate to advance personalised monitoring of solid tumor cancers with Droplet Digital PCR
Collaboration aims to grow clinical evidence supporting the use of Bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.
Bio-Rad launches first Ultrasensitive Multiplexed Digital PCR Assay for breast cancer mutation detection in clinical research
Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System
Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration
Dublin, Ireland : ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.
Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration
Antibodies validated for use with Bio-Rad’s Celselect Slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines
Castleford and London: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
AugaOne sensor system provides specific, real-time, and automated data to reduce mAb process development time New sensor will be exhibited at the Bioprocessing Summit, 18-21 March 2024, booth 66Linköping, Sweden, 21 March 2024:
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies
Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services Immunome signs deal to use Arrayjet platform in its in-house screening operationsEdinburgh,
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa studyCambridgeshire and Belfast, UK: Exploristics, a world-leading provider of biosimulat